Hemodilution

Subscribe to Selected New Research on Hemodilution

1193 relevant articles (74 outcomes, 115 trials/studies) found for this Therapy

Description: Reduction of blood viscosity usually by the addition of cell free solutions. Used clinically (1) in states of impaired microcirculation, (2) for replacement of intraoperative blood loss without homologous blood transfusion, and (3) in cardiopulmonary bypass and hypothermia.

Also Known As:

Hemodilutions

Relationship Network

Therapy Context: Research Results

Therapeutics: 5215

Hemodilution: 1193

Experts

1.	Ogata, Yoshitaka: 3 articles (08/2008 - 01/2004)
2.	Licker, Marc: 3 articles (02/2007 - 03/2005)
3.	Intaglietta, Marcos: 2 articles (08/2008 - 01/2008)
4.	Cabrales, Pedro: 2 articles (08/2008 - 01/2008)
5.	Moul, Judd W: 2 articles (07/2008 - 11/2007)
6.	Diaper, John: 2 articles (02/2007 - 03/2005)
7.	Sierra, Jorge: 2 articles (02/2007 - 03/2005)
8.	Ellenberger, Christoph: 2 articles (02/2007 - 03/2005)
9.	Piccinato, Carlos E: 2 articles (01/2006 - 01/2002)
10.	Farina, Jayme A: 2 articles (01/2006 - 01/2002)

Related Diseases

1.	Ischemia 05/01/1990 - "Regarding the long-term outcome, 45 minutes of ischemia with a normal Hct was associated with a marked decrease in kidney weight, GFR and urine osmolarity after four weeks of recovery, which could be prevented to a large extent by hemodilution" 01/01/1980 - "Optimal postischemic intensive monitoring and immobilization for 24-48 hours is important for improved outcome; 3) that immediate postischemic reperfusion pressure (MAP 110-150 mm Hg) significantly improves the outcome; 4) that heparinisation during ischemia has no protective effect and 5) that postischemic heparinisation and intravenous hemodilution does not ameliorate the outcome" 05/01/1996 - "BACKGROUND AND PURPOSE: Hemodilution is known to ameliorate the effects of focal ischemia when used shortly after cerebral arterial occlusion; however, it remains to be proved whether hemodilution will be effective when used at more clinically relevant times, ie, with some delay between the onset of ischemia and initiation of therapy" 05/01/1996 - "CONCLUSIONS: The current study indicates that hemodilution administered as much as 3 hours after ischemia is effective in reducing infarct size and improving neurological status" 01/01/1998 - "Hemodilution did not alter the muscle force or the extent or rate of force recovery after ischemia, which shows that the increased blood flow and improved microcirculation are not directly associated with changes in the sensitivity of muscle function to ischemia." Order ALL the reference details at left...
2.	Stroke (Strokes) 05/01/1992 - "BACKGROUND AND PURPOSE: In a previous single-center, randomized controlled trial including 102 patients treated in a stroke unit, we showed that rapid, modest hemodilution improved short-term clinical outcome in ischemic stroke patients" 05/01/2006 - "2) 37.5% of the patients had a temporary symptom aggravation after receiving a therapeutic regimen of blood-letting and chemotherapy, whereas, the stroke symptoms improved and became stable when treated with blood-letting combined with hemodilution and chemotherapy simultaneously" 03/01/1995 - "SETTING: Eleven primary care institutions (either hospitals or university clinics) participating in the Italian Acute Stroke Study on the efficacy of hemodilution and monosialoganglioside in acute ischemic stroke" 01/01/1996 - "A comparative study of the efficacy of normovolemic hemodilution and traditional therapy in treating ischemic stroke]" 11/01/1993 - "Indication and efficacy of hemodilution therapy on patients with acute ischemic stroke]" Order ALL the reference details at left...
3.	Hemorrhage 08/01/2002 - "BACKGROUND: Recently, various studies have questioned the efficacy of intraoperative acute normovolemic hemodilution (ANH) in reducing bleeding and the need for allogeneic transfusions in cardiac surgery" 05/01/2007 - "RESULTS: In patients undergoing coronary artery bypass grafting with a mini-CPB system, we observed decreased priming volumes with subsequent attenuation of on-pump hemodilution, improved hemostatic status with reduced platelet consumption and platelet activation, decreased postoperative bleeding and minimized transfusion requirements" 02/01/1998 - "In patients who have undergone hemodilution, the return of autologous blood may be delayed by the administration of PFC, and autologous RBCs may be saved for transfusion after surgical bleeding is stopped and PFC is cleared by the reticuloendothelial system" 08/01/2006 - "The aim of this study is to compare the effects of colloidal cardioplegia and blood cardioplegia in patients who underwent cardiac surgical procedures with cardiopulmonary bypass, and to evaluate their influence on hemodilution, bleeding and consumption of donor blood products in a retrospective clinical study" 11/01/1994 - "The results of our study indicate that hemodilution group tends to be more tolerant to bleeding than non-hemodilution group" Order ALL the reference details at left...
4.	Hypertension (High Blood Pressure) 05/01/2002 - "All DIND patients clinically improved in their Glasgow Coma Scale scores with induced hypertension, intentional hypervolemia, and/or hemodilution therapy (p =.01)" 04/01/2002 - "Cerebral blood flow promotion by hypertensive reperfusion and hemodilution has resulted in improved outcome in dogs, and brief hypertension after restoration of spontaneous circulation is associated with improved outcome in patients" 01/01/1993 - "After VF arrest of 12.5 min, hypertension plus hemodilution normalized the local (multifocal) cerebral hypoperfusion post-arrest and, again, inconsistently improved cerebral outcome" 01/01/1990 - "In Study B we resuscitated with hypertension and hemodilution" 07/01/2008 - "On the basis of our results, resistance area product can be used to estimate the optimal arterial blood pressure in hypervolemia/hypertension/hemodilution therapy" Order ALL the reference details at left...
5.	Shock 01/01/1986 - "In shock patients the hemodilution achieved with red cell free primary volume substitutes is an effective treatment for shock-induced microcirculatory disorders; furthermore, intentional hemodilution is the most effectual hemorheological therapy for the treatment of ischemic disease." 06/01/1978 - "Similarly, rats pretreated with the H(1)-receptor blockers demonstrated significantly greater compensatory hemodilution which continued late in shock" 05/01/2008 - "We simulated hemodilution that occurs during clinical resuscitation of hemorrhagic or hypovolemic shock, using healthy human donor whole blood (WB) ex vivo" 04/01/2007 - "The decisive approach in the therapy of hypovolemic shock is to initially attain normovolemia by rapid administration of volume replacement agents in the sense of controlled hemodilution" 04/01/2007 - "Hemodilution and infusion therapy for hypovolemic shock" Order ALL the reference details at left...

Related Drugs and Biologics

1.	Oxygen
2.	Hemoglobins (Hemoglobin)
3.	Hetastarch (Pentastarch)
4.	diaspirin-cross-linked hemoglobin
5.	Dextrans (Dextran)
6.	Heparin (Liquaemin)
7.	Serum Albumin
8.	Fibrin
9.	Reactive Oxygen Species (Oxygen Radicals)
10.	Nitroglycerin (Dynamite)

Related Therapies and Procedures

1.	Cardiopulmonary Bypass (Heart-Lung Bypass)
2.	Blood Transfusion (Blood Transfusions)
3.	Resuscitation
4.	Transplants (Transplant)
5.	Coronary Artery Bypass (Coronary Artery Bypass Surgery)

Best Treatments:
Research Summary Report
on Ischemia

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 2709 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>